Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

USA - NASDAQ:TSHA - US8776191061 - Common Stock

4.915 USD
+0.04 (+0.72%)
Last: 10/28/2025, 11:44:16 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TSHA. TSHA was compared to 534 industry peers in the Biotechnology industry. While TSHA seems to be doing ok healthwise, there are quite some concerns on its profitability. TSHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TSHA has reported negative net income.
In the past year TSHA has reported a negative cash flow from operations.
In the past 5 years TSHA always reported negative net income.
In the past 5 years TSHA always reported negative operating cash flow.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.82%, TSHA is in the better half of the industry, outperforming 70.04% of the companies in the same industry.
The Return On Equity of TSHA (-37.28%) is better than 73.41% of its industry peers.
Industry RankSector Rank
ROA -27.82%
ROE -37.28%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSHA has been increased compared to 1 year ago.
TSHA has more shares outstanding than it did 5 years ago.
TSHA has a worse debt/assets ratio than last year.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 6.90 indicates that TSHA is not in any danger for bankruptcy at the moment.
TSHA has a better Altman-Z score (6.90) than 76.78% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that TSHA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.17, TSHA is not doing good in the industry: 66.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 6.9
ROIC/WACCN/A
WACC8.69%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TSHA has a Current Ratio of 12.48. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
TSHA has a Current ratio of 12.48. This is amongst the best in the industry. TSHA outperforms 85.96% of its industry peers.
A Quick Ratio of 12.48 indicates that TSHA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.48, TSHA belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.48
Quick Ratio 12.48
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

TSHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.67%.
TSHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.11%.
EPS 1Y (TTM)-156.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-37.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.6%

3.2 Future

The Earnings Per Share is expected to grow by 21.41% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 124.14% on average over the next years. This is a very strong growth
EPS Next Y0.62%
EPS Next 2Y-8.38%
EPS Next 3Y-6.8%
EPS Next 5Y21.41%
Revenue Next Year-5.37%
Revenue Next 2Y-26.23%
Revenue Next 3Y21.35%
Revenue Next 5Y124.14%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TSHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

A cheap valuation may be justified as TSHA's earnings are expected to decrease with -6.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.38%
EPS Next 3Y-6.8%

More info and screens

0

5. Dividend

5.1 Amount

TSHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (10/28/2025, 11:44:16 AM)

4.915

+0.04 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-12 2025-11-12/amc
Inst Owners94.63%
Inst Owner Change0%
Ins Owners1.03%
Ins Owner Change-0.18%
Market Cap1.34B
Revenue(TTM)8.10M
Net Income(TTM)-92720000
Analysts84.44
Price Target8.84 (79.86%)
Short Float %17.31%
Short Ratio6.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.11%
Min EPS beat(2)-9.04%
Max EPS beat(2)15.26%
EPS beat(4)2
Avg EPS beat(4)4.42%
Min EPS beat(4)-9.04%
Max EPS beat(4)17.32%
EPS beat(8)6
Avg EPS beat(8)127.58%
EPS beat(12)8
Avg EPS beat(12)87.11%
EPS beat(16)9
Avg EPS beat(16)63.57%
Revenue beat(2)2
Avg Revenue beat(2)36.88%
Min Revenue beat(2)21.32%
Max Revenue beat(2)52.45%
Revenue beat(4)3
Avg Revenue beat(4)16.5%
Min Revenue beat(4)-14.14%
Max Revenue beat(4)52.45%
Revenue beat(8)6
Avg Revenue beat(8)24.06%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.77%
EPS NQ rev (1m)2.52%
EPS NQ rev (3m)-2.63%
EPS NY rev (1m)1.65%
EPS NY rev (3m)-6.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.36%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)9.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 165.57
P/FCF N/A
P/OCF N/A
P/B 5.39
P/tB 5.39
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.03
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.82%
ROE -37.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.66%
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.48
Quick Ratio 12.48
Altman-Z 6.9
F-Score4
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y0.62%
EPS Next 2Y-8.38%
EPS Next 3Y-6.8%
EPS Next 5Y21.41%
Revenue 1Y (TTM)-37.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.6%
Revenue Next Year-5.37%
Revenue Next 2Y-26.23%
Revenue Next 3Y21.35%
Revenue Next 5Y124.14%
EBIT growth 1Y-15.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.41%
EBIT Next 3Y42.49%
EBIT Next 5YN/A
FCF growth 1Y-34.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.81%
OCF growth 3YN/A
OCF growth 5YN/A

TAYSHA GENE THERAPIES INC / TSHA FAQ

What is the ChartMill fundamental rating of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSHA.


What is the valuation status of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.


What is the profitability of TSHA stock?

TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.


What is the financial health of TAYSHA GENE THERAPIES INC (TSHA) stock?

The financial health rating of TAYSHA GENE THERAPIES INC (TSHA) is 5 / 10.